A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering ...

Early data show promising platelet and molecular responses with monoclonal antibody monotherapy in ET and MF, with trials ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in ...

David Spigel, MD, medical oncologist and the chief scientific officer at Sarah Cannon Research Institute in Nashville, Tennessee, discusses the pivotal findings from the AIM-HIGH trial (NCT01817192), ...

An expert discusses how the treatment landscape for lower-risk MDS has evolved with multiple new options including luspatercept, imetelstat, and lenalidomide based on specific patient characteristics ...